SUPERNUS PHARMACEUTICALS INC (SUPN) Stock Fundamental Analysis
USA - NASDAQ:SUPN - US8684591089 - Common Stock
48.38 USD
-0.62 (-1.27%)
48.38 USD
0 (0%)
Taking everything into account, SUPN scores 7 out of 10 in our fundamental rating. SUPN was compared to 195 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making SUPN a very profitable company, without any liquidiy or solvency issues. SUPN is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! This makes SUPN very considerable for growth and quality investing!
1. Profitability
1.1 Basic Checks
SUPN had positive earnings in the past year.
SUPN had a positive operating cash flow in the past year.
In the past 5 years SUPN has always been profitable.
Each year in the past 5 years SUPN had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of 4.67%, SUPN belongs to the top of the industry, outperforming 87.69% of the companies in the same industry.
SUPN has a better Return On Equity (6.06%) than 86.15% of its industry peers.
With an excellent Return On Invested Capital value of 4.10%, SUPN belongs to the best of the industry, outperforming 81.54% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for SUPN is significantly below the industry average of 15.30%.
The 3 year average ROIC (2.70%) for SUPN is below the current ROIC(4.10%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.67% | ||
| ROE | 6.06% | ||
| ROIC | 4.1% |
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
1.3 Margins
SUPN has a Profit Margin of 9.70%. This is amongst the best in the industry. SUPN outperforms 85.64% of its industry peers.
SUPN's Profit Margin has declined in the last couple of years.
SUPN has a better Operating Margin (10.98%) than 84.10% of its industry peers.
In the last couple of years the Operating Margin of SUPN has declined.
SUPN has a Gross Margin of 89.87%. This is amongst the best in the industry. SUPN outperforms 93.33% of its industry peers.
In the last couple of years the Gross Margin of SUPN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.98% | ||
| PM (TTM) | 9.7% | ||
| GM | 89.87% |
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
2. Health
2.1 Basic Checks
SUPN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
SUPN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for SUPN has been increased compared to 5 years ago.
SUPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
SUPN has an Altman-Z score of 6.73. This indicates that SUPN is financially healthy and has little risk of bankruptcy at the moment.
SUPN's Altman-Z score of 6.73 is amongst the best of the industry. SUPN outperforms 81.03% of its industry peers.
There is no outstanding debt for SUPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 6.73 |
ROIC/WACC0.47
WACC8.69%
2.3 Liquidity
A Current Ratio of 2.58 indicates that SUPN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.58, SUPN is in line with its industry, outperforming 48.21% of the companies in the same industry.
A Quick Ratio of 2.43 indicates that SUPN has no problem at all paying its short term obligations.
The Quick ratio of SUPN (2.43) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.58 | ||
| Quick Ratio | 2.43 |
3. Growth
3.1 Past
SUPN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.93%, which is quite impressive.
The Earnings Per Share has been growing slightly by 6.93% on average over the past years.
SUPN shows a small growth in Revenue. In the last year, the Revenue has grown by 5.54%.
SUPN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.00% yearly.
EPS 1Y (TTM)50.93%
EPS 3Y44.39%
EPS 5Y6.93%
EPS Q2Q%16.88%
Revenue 1Y (TTM)5.54%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%-1.71%
3.2 Future
SUPN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.47% yearly.
The Revenue is expected to grow by 13.44% on average over the next years. This is quite good.
EPS Next Y-23.13%
EPS Next 2Y-8.21%
EPS Next 3Y9.72%
EPS Next 5Y18.47%
Revenue Next Year7.7%
Revenue Next 2Y13.56%
Revenue Next 3Y13.68%
Revenue Next 5Y13.44%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 14.84, the valuation of SUPN can be described as correct.
SUPN's Price/Earnings ratio is rather cheap when compared to the industry. SUPN is cheaper than 86.15% of the companies in the same industry.
SUPN is valuated rather cheaply when we compare the Price/Earnings ratio to 27.34, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 19.47 indicates a rather expensive valuation of SUPN.
SUPN's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. SUPN is cheaper than 75.38% of the companies in the same industry.
SUPN is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.86, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.84 | ||
| Fwd PE | 19.47 |
4.2 Price Multiples
SUPN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. SUPN is cheaper than 85.64% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, SUPN is valued cheaper than 86.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.59 | ||
| EV/EBITDA | 11.79 |
4.3 Compensation for Growth
SUPN has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)2.14
EPS Next 2Y-8.21%
EPS Next 3Y9.72%
5. Dividend
5.1 Amount
SUPN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
48.38
-0.62 (-1.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners109.54%
Inst Owner Change-0.01%
Ins Owners4.2%
Ins Owner Change2.53%
Market Cap2.71B
Analysts80
Price Target44.68 (-7.65%)
Short Float %9.35%
Short Ratio6.03
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.64%
Min EPS beat(2)15.55%
Max EPS beat(2)87.73%
EPS beat(4)4
Avg EPS beat(4)84.8%
Min EPS beat(4)15.55%
Max EPS beat(4)158.74%
EPS beat(8)7
Avg EPS beat(8)81.53%
EPS beat(12)8
Avg EPS beat(12)38.3%
EPS beat(16)10
Avg EPS beat(16)29.24%
Revenue beat(2)1
Avg Revenue beat(2)2.29%
Min Revenue beat(2)-0.71%
Max Revenue beat(2)5.29%
Revenue beat(4)3
Avg Revenue beat(4)6.02%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)9.98%
Revenue beat(8)6
Avg Revenue beat(8)5.08%
Revenue beat(12)8
Avg Revenue beat(12)2.78%
Revenue beat(16)11
Avg Revenue beat(16)2.43%
PT rev (1m)0%
PT rev (3m)12.31%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-45.57%
EPS NY rev (1m)4.87%
EPS NY rev (3m)31.04%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)11.37%
Revenue NY rev (1m)0.4%
Revenue NY rev (3m)9.54%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.84 | ||
| Fwd PE | 19.47 | ||
| P/S | 4.08 | ||
| P/FCF | 14.59 | ||
| P/OCF | 14.5 | ||
| P/B | 2.55 | ||
| P/tB | 5.83 | ||
| EV/EBITDA | 11.79 |
EPS(TTM)3.26
EY6.74%
EPS(NY)2.49
Fwd EY5.14%
FCF(TTM)3.31
FCFY6.85%
OCF(TTM)3.34
OCFY6.9%
SpS11.86
BVpS18.97
TBVpS8.3
PEG (NY)N/A
PEG (5Y)2.14
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.67% | ||
| ROE | 6.06% | ||
| ROCE | 6.66% | ||
| ROIC | 4.1% | ||
| ROICexc | 7.83% | ||
| ROICexgc | N/A | ||
| OM | 10.98% | ||
| PM (TTM) | 9.7% | ||
| GM | 89.87% | ||
| FCFM | 27.94% |
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
ROICexc(3y)4.39%
ROICexc(5y)6.6%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)4.82%
ROCE(5y)7.36%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y11.61%
ROICexc growth 5Y-8.56%
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
F-Score8
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 1.48% | ||
| Cap/Sales | 0.18% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 121.69% | ||
| Profit Quality | 288.18% | ||
| Current Ratio | 2.58 | ||
| Quick Ratio | 2.43 | ||
| Altman-Z | 6.73 |
F-Score8
WACC8.69%
ROIC/WACC0.47
Cap/Depr(3y)0.67%
Cap/Depr(5y)5.39%
Cap/Sales(3y)0.09%
Cap/Sales(5y)0.25%
Profit Quality(3y)2940.94%
Profit Quality(5y)1832.68%
High Growth Momentum
Growth
EPS 1Y (TTM)50.93%
EPS 3Y44.39%
EPS 5Y6.93%
EPS Q2Q%16.88%
EPS Next Y-23.13%
EPS Next 2Y-8.21%
EPS Next 3Y9.72%
EPS Next 5Y18.47%
Revenue 1Y (TTM)5.54%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%-1.71%
Revenue Next Year7.7%
Revenue Next 2Y13.56%
Revenue Next 3Y13.68%
Revenue Next 5Y13.44%
EBIT growth 1Y56.36%
EBIT growth 3Y-5.79%
EBIT growth 5Y-9.43%
EBIT Next Year-16.93%
EBIT Next 3Y25.95%
EBIT Next 5Y21.99%
FCF growth 1Y161.05%
FCF growth 3Y11.03%
FCF growth 5Y4.05%
OCF growth 1Y160.89%
OCF growth 3Y10.6%
OCF growth 5Y3.74%